Mesa Laboratories, Inc. (NASDAQ:MLAB) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus price objective of $240.00 for the company and are predicting that the company will post $1.57 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 88 out of 257 based on the ratings given to its competitors.
Several analysts have recently commented on the company. BidaskClub raised Mesa Laboratories from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 26th. TheStreet cut Mesa Laboratories from a “b-” rating to a “c” rating in a report on Tuesday, August 21st. Finally, ValuEngine cut Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, October 4th.
Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.14. The company had revenue of $24.87 million for the quarter, compared to the consensus estimate of $25.00 million. Mesa Laboratories had a positive return on equity of 16.65% and a negative net margin of 1.60%. As a group, equities analysts predict that Mesa Laboratories will post 7.09 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 17th. Stockholders of record on Friday, November 30th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.32%. Mesa Laboratories’s dividend payout ratio is currently 10.36%.
In related news, CFO John Sakys sold 1,000 shares of Mesa Laboratories stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $203.50, for a total transaction of $203,500.00. Following the completion of the transaction, the chief financial officer now directly owns 3,500 shares of the company’s stock, valued at $712,250. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Seg Ventures, Llc acquired 20,000 shares of Mesa Laboratories stock in a transaction that occurred on Sunday, December 30th. The shares were purchased at an average cost of $23.10 per share, with a total value of $462,000.00. Following the completion of the acquisition, the director now owns 120,000 shares of the company’s stock, valued at approximately $2,772,000. The disclosure for this purchase can be found here. Over the last three months, insiders bought 90,000 shares of company stock valued at $2,097,600 and sold 4,400 shares valued at $864,060. 15.00% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Sapphire Star Partners LP raised its holdings in Mesa Laboratories by 5.0% during the third quarter. Sapphire Star Partners LP now owns 5,619 shares of the medical instruments supplier’s stock worth $1,043,000 after purchasing an additional 268 shares during the last quarter. Bahl & Gaynor Inc. raised its holdings in Mesa Laboratories by 2.4% during the third quarter. Bahl & Gaynor Inc. now owns 13,786 shares of the medical instruments supplier’s stock worth $2,559,000 after purchasing an additional 323 shares during the last quarter. Yorktown Management & Research Co Inc raised its holdings in Mesa Laboratories by 9.7% during the third quarter. Yorktown Management & Research Co Inc now owns 3,910 shares of the medical instruments supplier’s stock worth $726,000 after purchasing an additional 346 shares during the last quarter. Rhumbline Advisers raised its holdings in Mesa Laboratories by 15.0% during the second quarter. Rhumbline Advisers now owns 3,176 shares of the medical instruments supplier’s stock worth $670,000 after purchasing an additional 415 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Mesa Laboratories by 2.7% during the third quarter. Bank of New York Mellon Corp now owns 19,358 shares of the medical instruments supplier’s stock worth $3,593,000 after purchasing an additional 500 shares during the last quarter. 73.08% of the stock is owned by hedge funds and other institutional investors.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Read More: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.